Silence Therapeutics is being acquired by Merck KGaA in a $1.3B all-cash deal at $20 per ADS, a 130% premium. The buyout caps upside, so the call moves to Hold pending shareholder and U.K. regulatory

What happened: Silence Therapeutics plc is being acquired by Merck KGaA in an all-cash deal, and the analyst downgraded SLN from Buy to Hold. Key numbers: $1.3B deal value; $20 per ADS, a 130% premium; divesiran achieved an 88% responder rate in phase 2 SANRECO for phlebotomy-dependent polycythemia vera. Why it matters: The buyout caps upside pending shareholder and U.K. regulatory approval, with limited further appreciation expected. If the acquisition fails, SLN faces funding risks for phase 3 studies, potentially requiring shareholder dilution or challenging capital raises.

Silence Therapeutics plc is being acquired by Merck KGaA in an all-cash deal, and the analyst downgraded SLN from Buy to Hold.

The buyout caps upside pending shareholder and U.K. regulatory approval, with limited further appreciation expected. If the acquisition fails, SLN faces funding risks for phase 3 studies, potentially requiring shareholder dilution or challenging capital raises.